Brocacef NL : Dutch Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Brocacef NL : Dutch Pharmaceutical Import Records from India — 2 Products, $473.3K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Brocacef NL : Dutch — Pharmaceutical Importer Profile (2026) | 2 Products, $473.3K Trade | TransData Nexus

Brocacef NL : Dutch

Pharmaceutical Importer · Netherlands · Advanced Diabetes Medications Focus · $473.3K Total Trade · DGFT Verified

Brocacef NL : Dutch is a pharmaceutical importer based in Netherlands with a total trade value of $473.3K across 2 products in 2 therapeutic categories. Based on 10 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Brocacef NL : Dutch sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Brocacef NL : Dutch — Import Portfolio & Supplier Network

Brocacef NL : Dutch import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Brocacef NL : Dutch?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$4.5M	586	100.0%

Brocacef NL : Dutch sources from 1 verified Indian supplier across 234 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Brocacef NL : Dutch Import?

Formulation	Value	Ships
Pharma drugs & medi pelgraz 6MG/0.6ML	$150.0K	3
Pharma drugs & medi amlodipine 5MG	$148.6K	6
Pharma drugs & medi tacrolimus ointmen	$148.2K	3
Pharma drugs & medi spironolactone 25mg3x10t(aco-netherlands as per	$106.4K	7
Pharma drugs & medi fulvestrant pfs	$100.0K	2
Pharma drugs & medi: sondelbay	$100.0K	2
Pharma drugs & medi pelgraz 6MG/0.6ML 1pfs(nl)ima_n as per	$100.0K	2
Pharma drugs & medi propranolol hcl	$96.0K	16
Pharma drugs & medi simvastatin 40MG 500t hdpe(accord-nl as per	$90.3K	5
Pharma drugs & medi mycofenolaat	$78.6K	3
Pharm drug&med:doxycycline accord 100mgeach uncoated dispersible TAB cont:doxycycline monohyd PH.EUR eq to doxy 100MG	$69.8K	6
Pharma drugs & medi eplerenone 50MG 3x10t(accord-nethrlan as per	$66.3K	5
Pharma drugs & medi vildagliptin 50MG 2x14t(accord-nl as per	$64.5K	2
Pharma drugs & medi spironolactone	$58.9K	5
Pharma drugs & medi oxybutynine hcl	$58.0K	11

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Vildagliptin	Advanced Diabetes Medications	$350.0K	7	3.4%	5
2	Carmustine	Advanced Oncology	$123.3K	3	0.5%	12

Brocacef NL : Dutch imports 2 pharmaceutical products across 2 categories into Netherlands totaling $473.3K.

Brocacef NL : Dutch — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Brocacef Groep, established in 1798 by Willem Brocades in Meppel, Netherlands, has evolved into a leading entity in the Dutch pharmaceutical sector. Over the centuries, it has expanded its operations to encompass a comprehensive range of services, including pharmaceutical wholesale, distribution, and retail. In 2002, Brocacef became part of the German PHOENIX Group, a prominent player in European pharmaceutical logistics and distribution. This integration has bolstered Brocacef's capabilities, enabling it to serve a diverse clientele comprising pharmacies, hospitals, general practitioners, nursing homes, healthcare insurers, and private individuals. (brocacef.nl)

Headquartered in Maarssen, Utrecht, Brocacef employs approximately 5,300 individuals. The company's extensive portfolio includes pharmaceuticals, medical devices, self-care products, and customized packaging solutions. Brocacef operates a nationwide network of 340 BENU pharmacies, offering consumers access to pharmaceutical care through various channels, including its own pharmacies, partner pharmacies, and BENU Direct. The company is committed to sustainability, aiming for complete CO₂ neutrality in its operations by 2030. (brocacef.nl)

2Distribution Network

Brocacef's distribution network is strategically designed to ensure efficient and reliable delivery of pharmaceutical products across the Netherlands. The company operates a sustainable fulfillment center in Amsterdam, which serves as a central hub for its logistics operations. This facility is equipped with advanced technologies to manage inventory, process orders, and coordinate deliveries effectively. Brocacef's logistics capabilities include temperature-controlled warehousing and qualified transport solutions, ensuring the integrity of pharmaceutical products throughout the supply chain. (brocacef.nl)

Geographically, Brocacef's reach extends beyond the Netherlands, leveraging the broader European network of the PHOENIX Group. This affiliation enables Brocacef to source and distribute products efficiently across Europe, enhancing its ability to meet the diverse needs of its clients. The company's distribution network is characterized by its responsiveness and adaptability, ensuring timely delivery of pharmaceutical products to various healthcare providers and consumers.

3Industry Role

Brocacef Groep holds a pivotal position in the Netherlands' pharmaceutical supply chain, functioning as a primary wholesaler and distributor. The company is deeply integrated into the entire pharmaceutical chain, providing services that span from sourcing and importing pharmaceutical products to distribution and retail. This comprehensive involvement allows Brocacef to maintain a unique position in Dutch pharmaceutical care, serving both healthcare consumers and the business market. (brocacef.nl)

In addition to its wholesale and distribution activities, Brocacef operates a network of BENU pharmacies, offering direct access to pharmaceutical care for consumers. This dual role as both a wholesaler and retailer enables Brocacef to have a significant impact on the Dutch pharmaceutical market, ensuring a steady supply of medications and healthcare products to a wide range of stakeholders.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Brocacef NL : Dutch

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Brocacef's sourcing strategy exhibits a high degree of concentration, with a total import value from India amounting to $473,000 USD across 10 shipments. The imported products are limited to two items within two therapeutic categories: Advanced Diabetes Medications and Advanced Oncology. This focused approach indicates a strategic choice to specialize in specific therapeutic areas, potentially allowing for optimized procurement processes and stronger supplier relationships.

The exclusive reliance on a single supplier, INTAS Pharmaceuticals Limited, for all 10 shipments suggests a stable and well-established partnership. This single-source dependency may mitigate complexities associated with managing multiple suppliers and ensure consistency in product quality and supply. However, it also exposes Brocacef to risks related to supply chain disruptions, regulatory changes, or operational issues within INTAS Pharmaceuticals. Diversifying the supplier base could enhance resilience and reduce potential vulnerabilities.

2Supply Chain Resilience

Brocacef's supply chain resilience concerning its Indian sourcing is influenced by its exclusive partnership with INTAS Pharmaceuticals Limited. While this singular relationship may streamline operations, it also presents challenges in terms of supply chain continuity. The absence of backup suppliers means that any disruptions affecting INTAS Pharmaceuticals could directly impact Brocacef's ability to meet market demands.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the regulatory authority overseeing pharmaceutical imports is the Dutch Medicines Evaluation Board (CBG). The CBG is responsible for evaluating and monitoring the safety, efficacy, and quality of medicines available in the Dutch market. Key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. Additionally, the European Medicines Agency (EMA) plays a significant role in harmonizing regulations across EU member states, including the Netherlands.

For Indian exporters, obtaining a marketing authorization from the CBG is essential for importing pharmaceutical products into the Netherlands. This process involves submitting comprehensive documentation demonstrating the product's quality, safety, and efficacy. The CBG evaluates these submissions in accordance with EU regulations, ensuring that imported medicines meet the necessary standards before they can be marketed in the Netherlands.

2Import Licensing & GMP

Import licensing requirements in the Netherlands are stringent to ensure the safety and efficacy of pharmaceutical products. Companies involved in the importation of medicinal products must obtain the necessary permits from the CBG. This includes a wholesale distribution authorization, which permits the holder to import, store, and distribute medicinal products within the Netherlands. Compliance with Good Manufacturing Practice (GMP) is mandatory, and imported products must be accompanied by certificates confirming adherence to EU GMP standards.

Brocacef NL : Dutch — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Brocacef's product strategy focuses on two primary therapeutic areas: Advanced Diabetes Medications and Advanced Oncology. The substantial import value of $350,000 USD for Vildagliptin and $123,000 USD

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Brocacef NL : Dutch

What products does Brocacef NL : Dutch import from India?

Brocacef NL : Dutch imports 2 pharmaceutical products across 2 categories. Top imports: Vildagliptin ($350.0K), Carmustine ($123.3K).

Who supplies pharmaceuticals to Brocacef NL : Dutch from India?

Brocacef NL : Dutch sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $4.5M).

What is Brocacef NL : Dutch's total pharmaceutical import value?

Brocacef NL : Dutch's total pharmaceutical import value from India is $473.3K, based on 10 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Brocacef NL : Dutch focus on?

Brocacef NL : Dutch imports across 2 categories. The largest: Advanced Diabetes Medications (73.9%), Advanced Oncology (26.1%).

Get Full Brocacef NL : Dutch Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.